Syndax Pharmaceuticals Inc. SNDX
$18.53
▲ +1.90% 24H
About
Syndax Pharmaceuticals Inc. is a commercial stage oncology innovator focused on developing cancer therapies for areas of significant unmet medical need. The company's product portfolio includes Revuforj, a menin inhibitor approved for treating relapsed or refractory NPM1-mutated acute myeloid leukemia in adult and pedi…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees270
TickerSNDX
Statistics
Market Cap$1.64B
Revenue (TTM)$172.4M
Net Income-$285.4M
Net Margin-165.6%
EPS$-3.29
P/E-5.44
P/S7.17
P/B37.40
EV/EBITDA-6.89
ROE-189.5%
Dividend Yield—
Price$18.53
Data: Twelve Data · Revenue = mcap / P/S